GTS Securities LLC Takes Position in Novo Nordisk A/S $NVO

GTS Securities LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, Holdings Channel.com reports. The fund bought 75,048 shares of the company’s stock, valued at approximately $3,598,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Flputnam Investment Management Co. purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $210,000. Capital Advisors Inc. OK grew its stake in shares of Novo Nordisk A/S by 4.7% during the second quarter. Capital Advisors Inc. OK now owns 25,516 shares of the company’s stock worth $1,223,000 after purchasing an additional 1,137 shares in the last quarter. Investors Asset Management of Georgia Inc. GA ADV acquired a new stake in Novo Nordisk A/S in the second quarter valued at $273,000. Ferguson Wellman Capital Management Inc. acquired a new stake in Novo Nordisk A/S in the second quarter valued at $227,000. Finally, North Star Asset Management Inc. purchased a new stake in Novo Nordisk A/S during the 2nd quarter worth about $1,950,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $45.59 on Friday. The business has a 50 day moving average price of $48.03 and a 200 day moving average price of $43.90. The company has a market capitalization of $203.56 billion, a P/E ratio of 11.15, a PEG ratio of 4.11 and a beta of 0.76. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Sell-side analysts expect that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. BMO Capital Markets reissued a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Thursday. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.